GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (OSTO:ATORX) » Definitions » Shiller PE Ratio

Alligator Bioscience AB (OSTO:ATORX) Shiller PE Ratio : (As of May. 10, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Alligator Bioscience AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alligator Bioscience AB Shiller PE Ratio Historical Data

The historical data trend for Alligator Bioscience AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB Shiller PE Ratio Chart

Alligator Bioscience AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alligator Bioscience AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alligator Bioscience AB's Shiller PE Ratio

For the Biotechnology subindustry, Alligator Bioscience AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Shiller PE Ratio falls into.


;
;

Alligator Bioscience AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alligator Bioscience AB's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Alligator Bioscience AB's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1110/132.8245*132.8245
=-1,110.000

Current CPI (Mar. 2025) = 132.8245.

Alligator Bioscience AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 0.000 100.225 0.000
201509 179.149 100.228 237.413
201512 -30.605 100.276 -40.539
201603 15.177 100.751 20.008
201606 -34.959 101.019 -45.966
201609 -5.853 101.138 -7.687
201612 -13.958 102.022 -18.172
201703 -12.157 102.022 -15.828
201706 -19.361 102.752 -25.027
201709 -16.209 103.279 -20.846
201712 8.105 103.793 10.372
201803 -26.565 103.962 -33.940
201806 -23.864 104.875 -30.224
201809 -25.214 105.679 -31.691
201812 -19.361 105.912 -24.281
201903 -27.916 105.886 -35.018
201906 -31.068 106.742 -38.660
201909 -35.570 107.214 -44.067
201912 -37.371 107.766 -46.061
202003 -28.167 106.563 -35.109
202006 -23.003 107.498 -28.423
202009 -20.186 107.635 -24.910
202012 -31.642 108.296 -38.809
202103 -21.522 108.360 -26.381
202106 -22.034 108.928 -26.868
202109 -23.059 110.338 -27.758
202112 -16.398 112.486 -19.363
202203 -10.249 114.825 -11.856
202206 -17.756 118.384 -19.922
202209 -19.447 122.296 -21.121
202212 -20.292 126.365 -21.329
202303 -23.674 127.042 -24.752
202306 -16.065 129.407 -16.489
202309 -6.764 130.224 -6.899
202312 -9.301 131.912 -9.365
202403 -8.064 132.205 -8.102
202406 -5.919 132.716 -5.924
202409 -7.610 132.304 -7.640
202412 -5.919 132.987 -5.912
202503 -1,110.000 132.825 -1,110.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alligator Bioscience AB  (OSTO:ATORX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alligator Bioscience AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alligator Bioscience AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheeletorget 1, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator Bioscience AB Headlines

No Headlines